BACKGROUND: Brain natriuretic peptide (BNP) is a vasoreactive peptide hormone, which is synthesized and secreted mainly from the heart ventricles. METHODS: Molecular forms of immunoreactive human brain natriuretic peptide (BNP) were examined. Chemically synthesized human BNP was added to whole blood samples from a healthy volunteer. The immunoreactive peptide was recovered by immunoaffinity chromatography followed by reversed-phase HPLC (RP-HPLC). Molecular form of immunoreactive BNP in plasma from heart failure patients was also examined. RESULTS: Sequential analysis and amino acid analysis of the peptide revealed that two amino acid residues were deleted from the amino terminus of BNP. When roughly classified according to molecular weight (MW), two forms of BNP (high-MW BNP and low-MW BNP) were observed. The estimated MW of high-MW BNP (36 kDa) was three times that of pro-BNP (12 kDa). CONCLUSIONS: Analysis of low-MW BNP by RP-HPLC revealed that a small amount of BNP 1-32 or des-SerPro-BNP (BNP 3-32) was contained in plasma from heart failure patients.
BACKGROUND:Brain natriuretic peptide (BNP) is a vasoreactive peptide hormone, which is synthesized and secreted mainly from the heart ventricles. METHODS: Molecular forms of immunoreactive humanbrain natriuretic peptide (BNP) were examined. Chemically synthesized humanBNP was added to whole blood samples from a healthy volunteer. The immunoreactive peptide was recovered by immunoaffinity chromatography followed by reversed-phase HPLC (RP-HPLC). Molecular form of immunoreactive BNP in plasma from heart failurepatients was also examined. RESULTS: Sequential analysis and amino acid analysis of the peptide revealed that two amino acid residues were deleted from the amino terminus of BNP. When roughly classified according to molecular weight (MW), two forms of BNP (high-MW BNP and low-MW BNP) were observed. The estimated MW of high-MW BNP (36 kDa) was three times that of pro-BNP (12 kDa). CONCLUSIONS: Analysis of low-MW BNP by RP-HPLC revealed that a small amount of BNP 1-32 or des-SerPro-BNP (BNP 3-32) was contained in plasma from heart failurepatients.
Authors: David L Garbers; Ted D Chrisman; Phi Wiegn; Takeshi Katafuchi; Joseph P Albanesi; Vincent Bielinski; Barbara Barylko; Margaret M Redfield; John C Burnett Journal: Trends Endocrinol Metab Date: 2006-06-30 Impact factor: 12.015
Authors: Selma F Mohammed; Josef Korinek; Horng H Chen; John C Burnett; Margaret M Redfield Journal: Rev Cardiovasc Med Date: 2008 Impact factor: 2.930
Authors: Adam M Hawkridge; Denise M Heublein; H Robert Bergen; Alessandro Cataliotti; John C Burnett; David C Muddiman Journal: Proc Natl Acad Sci U S A Date: 2005-11-17 Impact factor: 11.205
Authors: Jason M Tonne; Jarryd M Campbell; Alessandro Cataliotti; Seiga Ohmine; Tayaramma Thatava; Toshie Sakuma; Fima Macheret; Brenda K Huntley; John C Burnett; Yasuhiro Ikeda Journal: Clin Chem Date: 2011-04-11 Impact factor: 8.327
Authors: Guido Boerrigter; Lisa C Costello-Boerrigter; Gail J Harty; Brenda K Huntley; Alessandro Cataliotti; Harald Lapp; John C Burnett Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-04-22 Impact factor: 3.619